Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Treatment
6.1 Syngeneic Stem Cell Therapy
6.1.1 Neurology
6.1.2 Cardiology
6.1.3 Oncology
6.1.4 Diabetes
6.1.5 Hematology
6.2 Allogeneic Stem Cell Therapy
6.3 Autologous Stem Cell Therapy
Chapter 7 Market Segmentation by Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 Spain
7.2.3 UK
7.2.4 France
7.2.5 Russia
7.2.6 Italy
7.2.7 Others
7.3 Asia Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia & New Zealand
7.3.6 Others
7.4 The Middle East and Africa
7.4.1 Introduction
7.4.2 South Africa
7.4.3 Middle East Countries
7.4.4 Others
7.5 South America
7.5.1 Introduction
7.5.2 Argentina
7.5.3 Brazil
7.5.5 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles
9.1 Kite Pharma
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiative
9.2 Stemcells, Inc.
9.3 Advanced Cell Technology
9.4 Neuralstem, Inc.
9.5 NsGene
9.6 Osiris Therapeutics, Inc.
9.7 Geron Corporation
9.8 Aastrom Biosciences, Inc.
9.9 Invitrogen
9.10 Novocell (ViaCyte, Inc.)
9.11 Cellular Engineering Technologies Inc.
9.12 CellGenix GmbH
9.13 Athersys
9.14 Cytori Therapeutics, Inc.
9.15 Takara Bio USA Holdings, Inc.
Chapter 10 Market Insights
10.1 Insights of Industry Experts
10.2 Analyst Opinion (Market Understanding)
10.3 Investment Opportunities
Chapter 11 Appendix
11.1 List of Tables
11.2 List of Figures
